IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA)
CUSIP: 462260100
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 395,322,451
- Total 13F shares
- 261,537,672
- Share change
- +48,394,739
- Total reported value
- $713,890,828
- Put/Call ratio
- 57%
- Price per share
- $2.73
- Number of holders
- 259
- Value change
- +$134,068,635
- Number of buys
- 147
- Number of sells
- 98
Quarterly Holders Quick Answers
What is CUSIP 462260100?
CUSIP 462260100 identifies IOVA - IOVANCE BIOTHERAPEUTICS, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 462260100:
Top shareholders of IOVA - IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Wayne P. Rothbaum |
3/4/5
|
Director |
—
mixed-class rows
|
28,167,333
mixed-class rows
|
$257,731,097 | — | 01 Mar 2024 | |
| MHR FUND MANAGEMENT LLC |
13F
|
Company |
7.3%
|
28,967,103
|
$62,858,614 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.4%
from 13D/G
|
25,956,289
|
$56,325,148 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13D/G
13F
|
STATE STREET CORPORATION · Company |
5.1%
|
20,161,445
|
$55,847,203 | $0 | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
6.1%
|
24,058,983
|
$52,207,993 | — | 30 Sep 2025 | |
| PERCEPTIVE ADVISORS LLC |
13D/G
|
— |
3.8%
|
12,808,788
|
$45,599,285 | -$33,120,382 | 31 Mar 2025 | |
| Invenomic Capital Management LP |
13F
|
Company |
2.7%
|
10,541,608
|
$22,875,289 | — | 30 Sep 2025 | |
| Long Focus Capital Management, LLC |
13F
|
Company |
2.3%
|
9,116,507
|
$19,782,820 | — | 30 Sep 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
1.9%
|
7,618,132
|
$16,531,346 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
6,868,303
|
$14,905,575 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.7%
|
6,575,502
|
$14,268,839 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.6%
|
6,279,230
|
$13,625,928 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.4%
|
5,581,563
|
$12,111,992 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.1%
|
4,413,451
|
$9,577,189 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.97%
|
3,820,364
|
$8,290,189 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.84%
|
3,306,516
|
$7,175,140 | — | 30 Sep 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.76%
|
3,013,753
|
$6,539,845 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.71%
|
2,822,758
|
$6,126,547 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.69%
|
2,740,854
|
$5,947,653 | — | 30 Sep 2025 | |
| Merrill A. Mcpeak |
3/4/5
|
Director |
—
mixed-class rows
|
618,783
mixed-class rows
|
$5,661,865 | — | 01 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.63%
|
2,504,542
|
$5,434,856 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.62%
|
2,461,073
|
$5,340,529 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.52%
|
2,058,018
|
$4,467,000 | — | 30 Sep 2025 | |
| Orion Investment Co |
13F
|
Company |
0.47%
|
1,851,784
|
$4,018,371 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.39%
|
1,554,813
|
$3,375,000 | — | 30 Sep 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.38%
|
1,517,364
|
$3,292,680 | — | 30 Sep 2025 | |
| B Group, Inc. |
13F
|
Company |
0.38%
|
1,500,000
|
$3,255,000 | — | 30 Sep 2025 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.37%
|
1,451,372
|
$3,149,476 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.36%
|
1,413,662
|
$3,067,646 | — | 30 Sep 2025 | |
| C WorldWide Group Holding A/S |
13F
|
Company |
0.32%
|
1,260,000
|
$2,734,000 | — | 30 Sep 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.32%
|
1,251,481
|
$2,715,714 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.31%
|
1,223,831
|
$2,655,713 | — | 30 Sep 2025 | |
| Rhenman & Partners Asset Management AB |
13F
|
Company |
0.28%
|
1,097,827
|
$2,382,285 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.27%
|
1,059,000
|
$2,298,030 | — | 30 Sep 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.25%
|
976,707
|
$2,119,454 | — | 30 Sep 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.24%
|
945,470
|
$2,051,670 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.24%
|
936,687
|
$2,032,610 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.24%
|
936,504
|
$2,032,214 | — | 30 Sep 2025 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.23%
|
912,099
|
$1,979,255 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.2%
|
807,184
|
$1,751,587 | — | 30 Sep 2025 | |
| CM Management, LLC |
13F
|
Company |
0.18%
|
700,000
|
$1,519,000 | — | 30 Sep 2025 | |
| QVT Financial LP |
13F
|
Company |
0.17%
|
678,564
|
$1,472,484 | — | 30 Sep 2025 | |
| Voss Capital, LP |
13F
|
Company |
0.16%
|
650,000
|
$1,410,500 | — | 30 Sep 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.16%
|
645,456
|
$1,400,640 | — | 30 Sep 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.15%
|
611,397
|
$1,326,730 | — | 30 Sep 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.15%
|
607,210
|
$1,317,646 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.14%
|
567,680
|
$1,231,866 | — | 30 Sep 2025 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.14%
|
544,353
|
$1,181,246 | — | 30 Sep 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.14%
|
543,760
|
$1,179,959 | — | 30 Sep 2025 | |
| Swiss National Bank |
13F
|
Company |
0.13%
|
518,056
|
$1,124,182 | — | 30 Sep 2025 |
Institutional Holders of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) as of Q4 2025
As of 31 Dec 2025,
IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) was held by
259 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
261,537,672 shares.
The largest 10 holders included
BlackRock, Inc., MHR FUND MANAGEMENT LLC, VANGUARD GROUP INC, STATE STREET CORP, BANK OF AMERICA CORP /DE/, Invenomic Capital Management LP, MORGAN STANLEY, GOLDMAN SACHS GROUP INC, Long Focus Capital Management, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
259
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
249
Q4 2025 holders
259
Holder diff
10
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.